

# Luis Puig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/518218/publications.pdf>

Version: 2024-02-01

497  
papers

19,525  
citations

17440

63  
h-index

18647

119  
g-index

526  
all docs

526  
docs citations

526  
times ranked

13214  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 169-172.	1.2	5
2	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1652-1660.	2.2	20
3	Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2094-2101.	2.2	5
4	Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain): Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 1404-1418.	3.0	9
5	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. <i>Dermatology and Therapy</i> , 2022, 12, 61-78.	3.0	18
6	Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 827-834.	1.2	33
7	Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 51-64.	6.7	56
8	Pathophysiology of Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 13-19.	6.7	48
9	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	3.0	30
10	Psoriasis ungueal. <i>Actas Dermo-sifiligráficas</i> , 2022, 113, 481-490.	0.4	14
11	Retiform purpura in an 80-year-old woman. <i>International Journal of Dermatology</i> , 2022, , .	1.0	1
12	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.5	11
13	[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. <i>Actas Dermo-sifiligráficas</i> , 2022, 113, T261-T277.	0.4	4
14	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	4.1	12
15	Prevalence of most common skin diseases in Europe: a population-based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1088-1096.	2.4	52
16	Vulvar allergic contact dermatitis caused by <i>Magnolia officinalis</i> bark extract. <i>Contact Dermatitis</i> , 2022, 87, 96-97.	1.4	1
17	Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	2
18	Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE 2 and 3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1275-1283.	2.4	8

#	ARTICLE	IF	CITATIONS
19	A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 725-730.	2.1	6
20	Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate. <i>Journal of Ultrasound</i> , 2022, , 1.	1.3	0
21	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. <i>British Journal of Dermatology</i> , 2022, 186, 773-781.	1.5	32
22	Long-Term Benefitâ€“Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 167-184.	3.0	22
23	[Translated article] Nail Psoriasis. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2022, 113, T481-T490.	0.4	4
24	Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 941-953.	1.4	3
25	Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. <i>Advances in Therapy</i> , 2022, 39, 2862-2872.	2.9	15
26	Artritis psoriÃ¡sica. <i>Medicina ClÃ¡nica</i> , 2022, 159, 40-46.	0.6	9
27	Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational <i>psoriasis study of health outcomes</i> (<scp>PSoHO</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2087-2100.	2.4	15
28	Definition of minimal disease activity in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 422-430.	2.4	11
29	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINEâ€2 and â€3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 450-457.	2.4	14
30	An atypical and infrequent palmoplantar affection. <i>International Journal of Dermatology</i> , 2021, 60, 703-704.	1.0	0
31	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€“insights from a global registryâ€“based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	2.9	136
32	MetaanÃ¡lisis y comparaciones indirectas. MÃ©todos y paradigma: tratamiento biolÃ³gico de la psoriasis. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2021, 112, 203-215.	0.4	1
33	Occupational allergic contact dermatitis to isobornyl acrylate present in cell phone screen protectors. <i>Contact Dermatitis</i> , 2021, 84, 352-354.	1.4	6
34	Therapeutic targeting of the IL-13 pathway in skin inflammation. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 15-25.	3.0	16
35	Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab. <i>International Journal of Dermatology</i> , 2021, 60, e112-e114.	1.0	7
36	LRP1/CD91 is highly expressed in monocytes from patients with vitiligo â€“ even after repigmentation. <i>Experimental Dermatology</i> , 2021, 30, 390-395.	2.9	1

#	ARTICLE	IF	CITATIONS
37	Head-to-head comparison of biologics in psoriasis: better acceleration does not necessarily win all races. <i>British Journal of Dermatology</i> , 2021, 184, 992-993.	1.5	1
38	Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatological Treatment</i> , 2021, 32, 484-491.	2.2	4
39	Grover Disease with Focus on New Histopathological Patterns. , 2021, , 121-130.		0
40	Dual inhibition of IL-17A and IL-17F in psoriatic disease. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 2040622321110378.	2.5	26
41	Inhibidores de JAK: usos en dermatología. Parte 2: aplicaciones en psoriasis, dermatitis atópica y otras dermatosis. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 586-600.	0.4	9
42	The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 187-199.	3.0	13
43	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 797-806.	2.4	6
44	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905.	3.0	40
45	IL-13 antagonists in the treatment of atopic dermatitis. <i>Immunotherapy</i> , 2021, 13, 327-344.	2.0	5
46	Meta-analysis and Indirect Comparisons: on Methods, Paradigms, and Biologic Treatments for Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 203-215.	0.4	0
47	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	6.7	65
48	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.5	26
49	Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4344.	4.1	43
50	A case report of <i>PHF6</i> mosaicism: Beyond the classic <i>Börjeson-Forssman-Lehmann</i> syndrome. <i>Pediatric Dermatology</i> , 2021, 38, 919-925.	0.9	4
51	Burden of Psoriasis in Catalonia: Epidemiology, Associated Comorbidities, Health Care Utilization, and Sick Leave. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 425-433.	0.4	1
52	Carga de la psoriasis en Cataluña: datos epidemiológicos, comorbilidades asociadas, uso de recursos sanitarios e incapacidad laboral. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 425-433.	0.4	4
53	Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. <i>Dermatology and Therapy</i> , 2021, 11, 1319-1332.	3.0	23
54	Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. <i>Dermatology and Therapy</i> , 2021, 11, 1291-1304.	3.0	5

#	ARTICLE	IF	CITATIONS
55	Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses. <i>Actas Dermo-sifiliográficas</i> , 2021, 112, 586-586.	0.4	8
56	Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage. <i>JAMA Dermatology</i> , 2021, 157, 583.	4.1	28
57	Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. <i>Dermatology and Therapy</i> , 2021, 11, 1265-1275.	3.0	5
58	Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. <i>British Journal of Dermatology</i> , 2021, 185, 660-662.	1.5	17
59	Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?. <i>Drugs in R and D</i> , 2021, 21, 341-350.	2.2	10
60	Erythematous plaques with zosteriform distribution in a patient treated with TNF $\alpha$ inhibitor adalimumab for psoriasis. <i>International Journal of Dermatology</i> , 2021, 60, 1366-1367.	1.0	1
61	From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6740.	4.1	16
62	Pinch grafting: a unique application?. <i>Journal of Wound Care</i> , 2021, 30, 504-505.	1.2	0
63	Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE $\alpha$ 2 and AMAGINE $\alpha$ 3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2034-2044.	2.4	6
64	Adherence to a reliable PJI diagnostic protocol minimizes unsuspected positive cultures rate. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 653.	1.9	6
65	An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e828-e831.	2.4	1
66	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e636-e640.	2.4	18
67	Comment on "An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology". <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e89-e90.	1.2	0
68	Prepubertal retroareolar cysts. <i>Pediatric Dermatology</i> , 2021, 38, 1368-1369.	0.9	0
69	Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMItless open-label extension trial beyond 3 years of follow-up. <i>British Journal of Dermatology</i> , 2021, 185, 1135-1145.	1.5	28
70	Satisfactory treatment of mucocutaneous lesions in hereditary hemorrhagic telangiectasia patients with dual pulsed dye laser and neodymium: yttrium-aluminum-garnet. <i>Dermatologic Therapy</i> , 2021, 34, e15124.	1.7	3
71	Nodular scabies mimicking breast cancer skin metastasis. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 88, 88-89.	0.6	1
72	Nomenclature and clinical phenotypes of atopic dermatitis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110029.	2.5	43

#	ARTICLE	IF	CITATIONS
73	MicroRNA31 and MMP-1 contribute to the differentiated pathway of invasion -with enhanced epithelial-to-mesenchymal transition- in squamous cell carcinoma of the skin. Archives of Dermatological Research, 2021, , 1.	1.9	4
74	Authors'™ reply to Borg and Thoning: "Comment on: "Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study" American Journal of Clinical Dermatology, 2021, 22, 903-904.	6.7	1
75	Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. Vestnik Dermatologii i Venerologii, 2021, 97, 80-91.	0.6	2
76	New perspectives on the treatment of hidradenitis suppurativa. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110559.	2.5	26
77	Sequelae following infantile haemangiomas treated with propranolol. European Journal of Dermatology, 2021, 31, 785-790.	0.6	7
78	Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label <sc>OPTIMISE</sc> study. British Journal of Dermatology, 2020, 182, 304-315.	1.5	33
79	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase <sc>III</sc> clinical trials (re <sc>SURFACE</sc> 1 and re <sc>SURFACE</sc> 2) through 148 weeks. British Journal of Dermatology, 2020, 182, 605-617.	1.5	103
80	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment, 2020, 31, 606-614.	2.2	72
81	Effectiveness and safety of ustekinumab 90%mg in patients weighing 100%kg or less: a retrospective, observational, multicenter study. Journal of Dermatological Treatment, 2020, 31, 222-226.	2.2	8
82	Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. Journal of Dermatological Treatment, 2020, 31, 344-351.	2.2	11
83	Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. Journal of the American Academy of Dermatology, 2020, 82, 352-359.	1.2	56
84	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology, 2020, 82, 117-122.	1.2	120
85	The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1026-1036.	2.4	52
86	Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e21-e24.	2.4	5
87	Informes de posicionamiento terapéutico: utilidad y transparencia. Actas Dermo-sifiligráficas, 2020, 111, 3-6.	0.4	5
88	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews, 2020, 19, 102429.	5.8	197
89	Body dysmorphic disorder in patients with acne: a multicentre study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 370-376.	2.4	22
90	Psoriasis precipitated by timolol eye drops. A series of eight cases. Australasian Journal of Dermatology, 2020, 61, e91-e93.	0.7	2

#	ARTICLE	IF	CITATIONS
91	Adjusted treatment COMPARisons between guselkumab and ustekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. <i>British Journal of Dermatology</i> , 2020, 183, 276-284.	1.5	17
92	The safety of ixekizumab in psoriasis drug therapy. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 117-130.	2.4	12
93	Psoriasis Area and Severity Index vs. pharmacokinetics: can monitoring 4-week postinjection ustekinumab concentrations in patients with suboptimal response be clinically relevant?. <i>British Journal of Dermatology</i> , 2020, 182, 271-272.	1.5	0
94	Safety of ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	3.0	51
95	High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti-TNF Therapy. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1176-1183.	0.7	10
96	Biosimilares en el tratamiento de la psoriasis. Actualización. <i>Actas Dermo-sifilográficas</i> , 2020, 111, 809-814.	0.4	8
97	Encuesta de opinión a pacientes con psoriasis moderada-grave sobre la persistencia de los tratamientos biológicos. <i>Actas Dermo-sifilográficas</i> , 2020, 111, 691-694.	0.4	2
98	Biosimilars in the Treatment of Psoriasis: An Update. <i>Actas Dermo-sifilográficas</i> , 2020, 111, 809-814.	0.4	0
99	Follmann Balanitis: An Atypical Form of Primary Cutaneous Syphilis. <i>JAMA Dermatology</i> , 2020, 156, 1012.	4.1	5
100	Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab. <i>Dermatologic Therapy</i> , 2020, 33, e14180.	1.7	15
101	Opinion Survey on Persistence of Biologic Therapies in Patients with Moderate to Severe Psoriasis. <i>Actas Dermo-sifilográficas</i> , 2020, 111, 691-694.	0.4	0
102	<i>Saprochaete capitata</i> disseminated infection presenting as macular rash after haematopoietic stem cell transplantation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e748-e750.	2.4	1
103	Guselkumab in the treatment of moderate-to-severe plaque psoriasis. <i>Immunotherapy</i> , 2020, 12, 355-371.	2.0	11
104	Recomendaciones del Grupo de Psoriasis de la AEDV sobre el manejo de la consulta de psoriasis durante la pandemia por COVID-19. <i>Actas Dermo-sifilográficas</i> , 2020, 111, 802-804.	0.4	9
105	Sonication in shoulder surgery: is it necessary?. <i>International Orthopaedics</i> , 2020, 44, 1755-1759.	1.9	5
106	Clinical and genetic evaluation of six children with diffuse capillary malformation and undergrowth. <i>Pediatric Dermatology</i> , 2020, 37, 833-838.	0.9	7
107	Asymptomatic Exophytic Plaques on the Penis of a Patient With HIV Infection: Answer. <i>American Journal of Dermatopathology</i> , 2020, 42, 218-219.	0.6	0
108	Asymptomatic Exophytic Plaques on the Penis of a Patient With HIV Infection: Challenge. <i>American Journal of Dermatopathology</i> , 2020, 42, e28-e29.	0.6	0

#	ARTICLE	IF	CITATIONS
109	The safety of brodalumab for the treatment of psoriasis. Expert Opinion on Drug Safety, 2020, 19, 365-372.	2.4	16
110	Purple ulcerated nodules in a middle-aged man. International Journal of Dermatology, 2020, 59, e96-e98.	1.0	0
111	Good response to pulsed dye laser in patients with capillary malformation-arteriovenous malformation syndrome (CM-AVM). Pediatric Dermatology, 2020, 37, 342-344.	0.9	8
112	A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. JAMA Dermatology, 2020, 156, 384.	4.1	33
113	JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs, 2020, 80, 341-352.	10.9	101
114	The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma. Current Treatment Options in Oncology, 2020, 21, 47.	3.0	9
115	Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. American Journal of Clinical Dermatology, 2020, 21, 307-311.	6.7	60
116	Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. Expert Opinion on Drug Safety, 2020, 19, 423-432.	2.4	8
117	Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1744-1749.	2.4	22
118	Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltimMa1 and UltimMa2 studies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2830-2838.	2.4	46
119	Propranolol-resistant infantile hemangioma successfully treated with sirolimus. Pediatric Dermatology, 2020, 37, 684-686.	0.9	25
120	Comparison of Biologics and Oral Treatments for Plaque Psoriasis. JAMA Dermatology, 2020, 156, 258.	4.1	169
121	Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk. Acta Dermato-Venereologica, 2020, 100, 1-8.	1.3	20
122	Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council. JAAD International, 2020, 1, 224-230.	2.2	3
123	An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis. Acta Dermato-Venereologica, 2020, 100, adv00344.	1.3	5
124	Spongiotic and Psoriasiform Dermatitis. , 2020, , 5-40.		0
125	Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Analysis from a Long-term Clinical Study. Journal of Clinical and Aesthetic Dermatology, 2020, 13, 18-22.	0.1	5
126	Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology, 2019, 143, 1021-1026.	2.9	165



#	ARTICLE	IF	CITATIONS
127	Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1405-1409.	1.2	14
128	Significant weight loss improves and prevents psoriasis and psoriatic arthritis in obese patients: a Critically Appraised Topic and a call to action. <i>British Journal of Dermatology</i> , 2019, 181, 884-885.	1.5	1
129	Patient-Reported Outcomes in Psoriasis Validated in Spain: PROs and Cons. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 518-519.	0.4	0
130	Biosimilars for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 993-1000.	3.1	30
131	Incremental Cost per Responder (PASI-75, PASI-90 and PASI-100) Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis: Spain 2018. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 517-518.	0.4	1
132	Update on Topical Treatments for Psoriasis: The Role of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 115-123.	0.4	3
133	Cutibacterium acnes in primary reverse shoulder arthroplasty: from skin to deep layers. <i>Journal of Shoulder and Elbow Surgery</i> , 2019, 28, 839-846.	2.6	43
134	British Association of Dermatologists Biologic Interventions Register delivers: infliximab increases risk of serious infections. <i>British Journal of Dermatology</i> , 2019, 180, 257-258.	1.5	0
135	Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review. <i>Dermatology and Therapy</i> , 2019, 9, 479-496.	3.0	1
136	Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1214-1223.	2.4	8
137	Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. <i>Archives of Dermatological Research</i> , 2019, 311, 421-424.	1.9	36
138	Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 589-597.	3.0	12
139	Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross-sectional study among 2465 patients. <i>British Journal of Dermatology</i> , 2019, 181, 1198-1206.	1.5	24
140	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naïve Patients from 2 Phase III Ustekinumab Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1458-1461.	2.0	11
141	Biosimilars for Psoriasis: Experience from Europe. <i>Current Dermatology Reports</i> , 2019, 8, 26-34.	2.1	6
142	Iceberg sign as a dermoscopic clue of actinic keratosis neglecta. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e254-e256.	2.4	3
143	Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. <i>British Journal of Dermatology</i> , 2019, 180, 67-75.	1.5	33
144	Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 355-364.	0.9	44

#	ARTICLE	IF	CITATIONS
145	The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 541-554.	1.3	112
146	Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis. <i>Cancer Biology and Therapy</i> , 2019, 20, 237-239.	3.4	6
147	La efectividad del tratamiento con omalizumab en la vida real es menor en pacientes con urticaria crónica de más de 18 meses de evolución y tratamiento inmunosupresor previo. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 289-296.	0.4	2
148	Actualización del tratamiento tópico en psoriasis: aportación de la combinación de calcipotriol y dipropionato de betametasona en espuma. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 115-123.	0.4	7
149	Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 553-559.	2.4	51
150	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 70-79.e3.	1.2	77
151	Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. <i>Journal of Dermatological Treatment</i> , 2019, 30, 424-429.	2.2	57
152	Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from <scp>EPIDEPSO</scp>. <i>British Journal of Dermatology</i> , 2019, 180, 397-403.	1.5	16
153	Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. <i>Journal of Dermatological Treatment</i> , 2019, 30, 27-34.	2.2	20
154	Milia, una reacción infrecuente tras terapia fotodinámica. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 71-74.	0.4	0
155	Desarrollo y validación preliminar del instrumento HSQoL-24 para evaluar calidad de vida en pacientes con hidradenitis supurativa. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 554-560.	0.4	11
156	Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes. <i>Acta Dermato-Venereologica</i> , 2019, 99, 971-977.	1.3	23
157	Patient reported outcomes en psoriasis validados en España: PROs y contras. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 518-519.	0.4	0
158	Análisis del coste incremental por respondedor (PASI75, PASI90 y PASI100) basado en un metaanálisis en red de tratamientos biológicos para la psoriasis: España 2018. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 517-518.	0.4	3
159	Carcinoma en coraza. <i>Actas Dermo-sifilográficas</i> , 2019, 110, e2.	0.4	0
160	The depth of follicular extension in actinic keratosis correlates with the depth of invasion in squamous cell carcinoma: implication for clinical treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1657-1661.	2.4	9
161	Epidemiology of atopic dermatitis in adults: Results from an international survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1284-1293.	5.7	546
162	Líneas de demarcación pigmentarias tipo B en gestante. <i>Actas Dermo-sifilográficas</i> , 2018, 109, 446.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Results of cement spacer sonication in the second stage of two-stage treatment of shoulder arthroplasty infection. <i>Journal of Orthopaedic Surgery and Research</i> , 2018, 13, 58.	2.3	17
164	GCAT   Genomes for life: a prospective cohort study of the genomes of Catalonia. <i>BMJ Open</i> , 2018, 8, e018324.	1.9	31
165	Subclinical enthesopathy of extensor digitorum tendon is highly prevalent and associated with clinical and ultrasound alterations of the adjacent fingernails in patients with psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1728-1736.	2.4	21
166	Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. <i>British Journal of Dermatology</i> , 2018, 178, 1297-1307.	1.5	8
167	Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 23-32.	6.7	64
168	Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. <i>British Journal of Dermatology</i> , 2018, 178, 114-123.	1.5	269
169	Novel clinical and molecular findings in Spanish patients with naevoid basal cell carcinoma syndrome. <i>British Journal of Dermatology</i> , 2018, 178, 198-206.	1.5	5
170	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 741-748.	1.2	22
171	Sesgo en el Cuestionario de productividad laboral y deterioro de las actividades: psoriasis (WPAI:PSO) Tj ETQq1 1 0,784314 rgBT /Over	0.4	8
172	Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. <i>Journal of Dermatological Treatment</i> , 2018, 29, 334-346.	2.2	39
173	Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine. <i>JAMA Dermatology</i> , 2018, 154, 99.	4.1	29
174	Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others. <i>Current Problems in Dermatology</i> , 2018, 53, 49-63.	0.7	80
175	Epithelial-mesenchymal transition contributes to invasion in squamous cell carcinomas originated from actinic keratosis through the differentiated pathway, whereas proliferation plays a more significant role in the classical pathway. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 581-586.	2.4	24
176	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. <i>BioDrugs</i> , 2018, 32, 397-404.	4.6	82
177	Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 824-830.e2.	1.2	55
178	Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. <i>Acta Dermato-Venereologica</i> , 2018, 98, 98-102.	1.3	21
179	Lower lip capillary malformation associated with lymphatic malformation without overgrowth: Part of the spectrum of CLAPO syndrome. <i>Pediatric Dermatology</i> , 2018, 35, e243-e244.	0.9	6
180	Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 58.	4.1	90

#	ARTICLE	IF	CITATIONS
181	Dystrophic Calcification in a Patient with Primary Localized Cutaneous Nodular Amyloidosis: An Uncommon Ultrasound Finding. <i>Acta Dermato-Venereologica</i> , 2018, 98, 144-145.	1.3	2
182	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018, 392, 650-661.	13.7	457
183	Oral ulcers in heart transplant patient. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2018, 84, 750.	0.6	5
184	Triple paradoxical reaction due to adalimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e71-e73.	2.4	3
185	Baños de parafina para el tratamiento del eccema crónico de las manos. <i>Actas Dermo-sifilográficas</i> , 2017, 108, 261-264.	0.4	3
186	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , 2017, 18, 273-280.	6.7	29
187	Malformación glomovenosa congénita en placas: 11 años de seguimiento y respuesta al tratamiento con láser combinado PDL/Nd: YAG. <i>Actas Dermo-sifilográficas</i> , 2017, 108, 72-74.	0.4	7
188	Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. <i>Journal of Dermatological Treatment</i> , 2017, 28, 492-499.	2.2	44
189	A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1176-1182.	2.4	10
190	The role of IL 23 in the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 525-534.	3.0	111
191	Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 253-271.	6.7	49
192	Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. <i>Advances in Therapy</i> , 2017, 34, 1327-1339.	2.9	23
193	The safety of ustekinumab for the treatment of psoriatic arthritis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 733-742.	2.4	23
194	European consensus statement on phenotypes of pustular psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1792-1799.	2.4	269
195	Psoriasis: inequality or individualized care?. <i>British Journal of Dermatology</i> , 2017, 176, 1111-1113.	1.5	3
196	Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 1006-1016.	4.7	21
197	The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1196-1207.	2.4	33
198	Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. <i>Actas Dermo-sifilográficas</i> , 2017, 108, 184-191.	0.4	0

#	ARTICLE	IF	CITATIONS
199	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. British Journal of Dermatology, 2017, 177, 587-590.	1.5	10
200	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). British Journal of Dermatology, 2017, 177, 197-205.	1.5	36
201	Registries and biologics: disease populations matter. British Journal of Dermatology, 2017, 176, 567-568.	1.5	0
202	Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. British Journal of Dermatology, 2017, 176, 1195-1203.	1.5	37
203	Merece la pena hacerse miembro de la European Academy of Dermatology and Venereology (EADV). Actas Dermo-sifiligráficas, 2017, 108, 605.	0.4	0
204	Choice of first-line biologic therapy in psoriasis: understanding the past and shaping the future?. British Journal of Dermatology, 2017, 177, 623-624.	1.5	1
205	Infantile hemangiomas with minimal or arrested growth associated with soft tissue hypertrophy: a case series of 10 patients. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1924-1929.	2.4	5
206	Serum C-reactive protein in patients undergoing elective shoulder arthroplasty. Prospective study. Journal of Orthopaedic Science, 2017, 22, 858-861.	1.1	6
207	Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. Journal of Dermatological Treatment, 2017, 28, 623-630.	2.2	16
208	Development and validation of the International Hidradenitis Suppurativa Severity Score System (I-HSS). British Journal of Dermatology, 2017, 177, 1401-1409.	1.5	301
209	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology, 2017, 177, 1495-1502.	1.5	48
210	The role of IL-23 and the IL-23/Th17 immune axis in the pathogenesis and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1616-1626.	2.4	187
211	Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 213-220.	2.4	60
212	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 294-303.	2.4	12
213	Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. British Journal of Dermatology, 2017, 177, 47-62.	1.5	218
214	Enfermedad inflamatoria intestinal: abordaje conjunto digestivo-dermatológico. Actas Dermo-sifiligráficas, 2017, 108, 184-191.	0.4	2
215	Biosimilars for psoriasis: clinical studies to determine similarity. British Journal of Dermatology, 2017, 177, 23-33.	1.5	16
216	The AGEs of Psoriasis: A Biomarker for Severity and a Pathogenetic Link to Comorbidities. Acta Dermato-Venereologica, 2017, 97, 775.	1.3	2

#	ARTICLE	IF	CITATIONS
217	Brodalumab: The first anti-IL-17 receptor agent for psoriasis. <i>Drugs of Today</i> , 2017, 53, 283.	1.1	41
218	Crusted (Norwegian) scabies: an under-recognized infestation characterized by an atypical presentation and delayed diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 483-485.	2.4	13
219	Defining effective approaches to the reduction or elimination of biologic therapy immunogenicity and loss of response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 321-323.	2.4	0
220	Treatment of psoriasis with etanercept: the typical patient profile. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1092-1099.	2.4	17
221	Biosimilars in psoriasis 2015: what is next?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 467-469.	2.4	1
222	Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1-18.	2.4	105
223	Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. <i>British Journal of Dermatology</i> , 2016, 174, 282-286.	1.5	38
224	Allergic contact dermatitis to silver in a patient treated with silver sulphadiazine after a burn. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 365-366.	2.4	15
225	ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1066-1072.	1.2	65
226	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016, 14, 133.	5.5	97
227	Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1156-1161.	1.2	39
228	Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1812-1822.	3.4	27
229	Vascular Stains: Proposal for a Clinical Classification to Improve Diagnosis and Management. <i>Pediatric Dermatology</i> , 2016, 33, 570-584.	0.9	39
230	Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy. <i>JAMA Dermatology</i> , 2016, 152, 1239.	4.1	99
231	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1984-1988.	0.9	131
232	Interleukin-17 in skin: psoriasis and yonder. <i>British Journal of Dermatology</i> , 2016, 175, 859-860.	1.5	0
233	Modelo de eficiencia de los fármacos biológicos en el tratamiento de la psoriasis moderada-grave durante un año en las condiciones de uso en España. <i>Actas Dermo-sifilográficas</i> , 2016, 107, 34-43.	0.4	7
234	Cytokine Pathways and the Role of Dysbiosis in Psoriasis, Psoriatic Arthritis, and Crohn Disease. <i>Actas Dermo-sifilográficas</i> , 2016, 107, 95-97.	0.4	0

#	ARTICLE	IF	CITATIONS
235	Model for Assessing the Efficiency of Biologic Drugs in the Treatment of Moderate to Severe Psoriasis for 1 Year in Clinical Practice in Spain. <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 34-43.	0.4	3
236	Psoriasis, artritis psoriásica y enfermedad de Crohn: circuitos de citocinas y papel de la disbiosis. <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 95-97.	0.4	1
237	Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 593-602.	0.7	27
238	Metotrexato en psoriasis moderada-grave: revisión de la literatura y recomendaciones de experto. <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 194-206.	0.4	37
239	The role of biologics in the treatment of moderate-to-severe plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2016, 152, 28-35.	0.2	2
240	Impact of Alexithymia and Disease Characteristics on Work Productivity and Activity In Psoriasis Patients With Short Disease Duration: Epidepso Multicentre Study. <i>Value in Health</i> , 2015, 18, A425-A426.	0.3	2
241	On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 131-134.	1.5	2
242	Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2002-2010.	2.4	139
243	Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1739-1749.	3.4	87
244	Epidermolytic Hyperkeratosis. <i>American Journal of Dermatopathology</i> , 2015, 37, 734-735.	0.6	4
245	Improving patient outcomes in psoriasis: strategies to ensure treatment adherence. <i>Psoriasis: Targets and Therapy</i> , 2015, 5, 109.	2.2	9
246	Actinic keratosis with atypical basal cells (<sc>AK</sc>) is the most common lesion associated with invasive squamous cell carcinoma of the skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 991-997.	2.4	188
247	A deletion atADAMTS9-MAGI1locus is associated with psoriatic arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1875-1881.	0.9	18
248	The Value of Achieving Complete or Near Complete Resolution of Psoriasis. <i>Value in Health</i> , 2015, 18, A427.	0.3	1
249	Real World Skin Clearance Rates for Biologic Treatments In Patients With Moderate to Severe Plaque Psoriasis: Interim Results From A Large Prospective, Observational Study. <i>Value in Health</i> , 2015, 18, A429.	0.3	0
250	Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain. <i>European Journal of Dermatology</i> , 2015, 25, 410-417.	0.6	3
251	Immune-Mediated Inflammatory Diseases and Other Comorbidities in Patients With Psoriasis: Baseline Characteristics of Patients in the AQUILES Study. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 35-43.	0.4	9
252	Enfermedades inflamatorias mediadas por inmunidad y otras comorbilidades en pacientes con psoriasis. Características basales de la cohorte de pacientes con psoriasis del estudio AQUILES. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 35-43.	0.4	27

#	ARTICLE	IF	CITATIONS
253	Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. <i>Journal of Dermatological Treatment</i> , 2015, 26, 318-325.	2.2	12
254	Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 7-15.	2.2	32
255	Etanercept en el tratamiento de la artritis psoriásica. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 252-259.	0.4	4
256	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 306-315.	2.6	71
257	<scp>PASI</scp>90 response: the new standard in therapeutic efficacy for psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 645-648.	2.4	150
258	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1156-1163.	2.4	20
259	Biosimilars in Dermatology: Current Situation (Part I). <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 545-549.	0.4	1
260	Hidradenitis suppurativa: nuevas oportunidades para una enfermedad dermatológica huérfana. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 448-451.	0.4	4
261	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , 2015, 26, 103-112.	2.2	50
262	Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis. <i>Dermatology</i> , 2015, 230, 46-54.	2.1	35
263	Chronic Ulceration and Fibrosis of the Forearm. <i>JAMA Dermatology</i> , 2015, 151, 331.	4.1	2
264	Etanercept in the Treatment of Psoriatic Arthritis. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 252-259.	0.4	1
265	Treatment goals for psoriasis: Should PASI 90 become the standard of care?. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 155-157.	0.4	43
266	Systemic methotrexate for the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 553-563.	3.0	43
267	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 1318-1328.	27.0	656
268	Monoclonal gammopathy of undetermined significance (<scp>MGUS</scp>) in patients with psoriasis may be associated with long-term treatment with efalizumab, but not with anti-TNFα treatments or ustekinumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 609-611.	2.4	4
269	Biosimilars in Dermatology: Current Situation (Part II). <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 550-554.	0.4	5
270	Secukinumab (AIN457) for the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1177-1188.	3.0	20



#	ARTICLE	IF	CITATIONS
271	Biosimilares en dermatología. Situación actual (parte i). Actas Dermo-sifiliográficas, 2015, 106, 545-549.	0.4	10
272	Biosimilares en dermatología. Situación actual (parte ii). Actas Dermo-sifiliográficas, 2015, 106, 550-554.	0.4	5
273	Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. Pharmacogenomics Journal, 2015, 15, 322-325.	2.0	21
274	Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 224-231.	2.4	31
275	Predictors of biologic treatment of psoriasis: a non-interventional study. ClinicoEconomics and Outcomes Research, 2014, 6, 93.	1.9	5
276	Conventional and molecular diagnostic strategies for prosthetic joint infections. Expert Review of Molecular Diagnostics, 2014, 14, 83-96.	3.1	24
277	Mohs micrographic surgery for basal cell carcinomas: results of a Spanish retrospective study and Kaplan-Meier survival analysis of tumour recurrence. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1363-1369.	2.4	13
278	Acute Severe Methotrexate Toxicity in Patients with Psoriasis: A Case Series and Discussion. Dermatology, 2014, 229, 306-309.	2.1	28
279	Incremental Cost-Effectiveness Ratio Analysis of Biologic Treatments for Psoriasis at Clinically Significant Evaluation Time Points. Actas Dermo-sifiliográficas, 2014, 105, 951-953.	0.4	3
280	Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1514-1521.	2.4	31
281	Efficacy of biologics in the treatment of moderate to severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1633-1653.	2.4	65
282	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of the Rheumatic Diseases, 2014, 73, 990-999.	0.9	576
283	Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. European Journal of Dermatology, 2014, 24, 662-669.	0.6	4
284	Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common comorbidities in patients with moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1661-1669.	2.4	36
285	Biosimilars and Reference Biologics: Decisions on Biosimilar Interchangeability Require the Involvement of Dermatologists. Actas Dermo-sifiliográficas, 2014, 105, 435-437.	0.4	0
286	Advantages of sonication fluid culture for the diagnosis of prosthetic joint infection. Journal of Infection, 2014, 69, 35-41.	3.3	108
287	Configo herpetiforme con evolución a configo foliáceo. Descripción de un caso. Actas Dermo-sifiliográficas, 2014, 105, 526-528.	0.4	4
288	Tratamiento de la psoriasis en placas moderada a grave con fármacos biológicos: análisis del sobrecoste de la intensificación temporal frente a cambio a otro biológico en caso de fracaso secundario. Actas Dermo-sifiliográficas, 2014, 105, 401-412.	0.4	19

#	ARTICLE	IF	CITATIONS
289	Recommendations for the Coordinated Management of Psoriatic Arthritis by Rheumatologists and Dermatologists: A Delphi Study. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 216-232.	0.4	14
290	Análisis de coste-eficacia incremental de los tratamientos biológicos para la psoriasis en los momentos de valoración significativos para la práctica clínica. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 951-953.	0.4	7
291	Unidades multidisciplinares de artritis psoriásica: sobre objetivos y modelos. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 325-327.	0.4	7
292	Methotrexate: New Therapeutic Approaches. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 583-589.	0.4	16
293	IL-17 in psoriasis. The final frontier or just another brick in the wall?. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 6-8.	0.4	0
294	Therapeutic implications of IL-17A blockade in psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 1-5.	0.4	0
295	Psoriasis beyond the skin: a review of the literature on cardiometabolic and psychological co-morbidities of psoriasis. <i>European Journal of Dermatology</i> , 2014, 24, 305-311.	0.6	30
296	Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. <i>Journal of Dermatological Treatment</i> , 2014, 25, 470-481.	2.2	16
297	Psoriasis In Pregnancy: A Review (II). <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 813-821.	0.4	0
298	Evidence-Based Guidelines of the Spanish Psoriasis Group on the Use of Biologic Therapy in Patients With Psoriasis in Difficult-to-Treat Sites (Nails, Scalp, Palms, and Soles). <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 923-934.	0.4	12
299	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the <sc>TRANSIT</sc> randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.5	37
300	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.5	24
301	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1000-1006.	0.9	255
302	A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 438-453.	2.4	122
303	Secukinumab in Plaque Psoriasis – Results of Two Phase 3 Trials. <i>New England Journal of Medicine</i> , 2014, 371, 326-338.	27.0	1,675
304	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	1.2	423
305	Discapacidad acumulada en el transcurso vital: la cicatriz de la psoriasis en la vida del paciente. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 128-134.	0.4	37
306	Metotrexato: novedades terapéuticas. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 583-589.	0.4	30

#	ARTICLE	IF	CITATIONS
307	Treatment of Moderate to Severe Plaque Psoriasis With Biologics: Analysis of the Additional Cost of Temporary Dose Escalation vs Switch to Another Biologic After Failure of Maintenance Therapy. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 401-412.	0.4	3
308	Multidisciplinary Teams for Psoriatic Arthritis: On Aims and Approaches. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 325-327.	0.4	4
309	Elaboración mediante el método Delphi de recomendaciones para el manejo coordinado (reumatólogo/dermatólogo) de la artritis psoriásica. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 216-232.	0.4	24
310	Leishmaniasis cutánea en un paciente con artritis psoriásica tratado con infliximab: tratamiento con crioterapia y Glucantime® intralesional. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 714-716.	0.4	6
311	Psoriasis y embarazo: revisión (I). <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 734-743.	0.4	17
312	Psoriasis y embarazo: revisión (II). <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 813-821.	0.4	2
313	Anetoderma primaria asociada a síndrome de Sjögren primario y anticuerpos anticardiolipina. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 99-101.	0.4	5
314	Psoriasis: bases genéticas y patogénicas. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 535-545.	0.4	36
315	Los tratamientos biológicos de la psoriasis moderada a grave no son alternativas terapéuticas equivalentes. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 483-486.	0.4	5
316	Directrices del grupo español de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biológicos en pacientes con psoriasis en localizaciones de difícil tratamiento (uñas, cuero cabelludo). <i>TJ ETQ0 004rgBT / Overlock 10</i>	0.4	0
317	The Pathogenesis and Genetics of Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 535-545.	0.4	26
318	Biosimilares y biológicos de referencia: la intercambiabilidad de los biosimilares requiere la participación del dermatólogo. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 435-437.	0.4	3
319	Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e257-60.	2.4	12
320	Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 241-258.	3.4	116
321	National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. <i>Archives of Dermatological Research</i> , 2013, 305, 637-643.	1.9	7
322	Prosthesis Failure Within 2 Years of Implantation Is Highly Predictive of Infection. <i>Clinical Orthopaedics and Related Research</i> , 2013, 471, 3672-3678.	1.5	93
323	Late-Onset Inflammatory Adverse Reactions Related to Soft Tissue Filler Injections. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 97-108.	6.5	102
324	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <i>Lancet, The</i> , 2013, 382, 780-789.	13.7	688

#	ARTICLE	IF	CITATIONS
325	Impacto en la calidad de vida relacionada con la salud de pacientes con psoriasis activa y estable. Estudio PSO-LIFE. Actas Dermo-sifiliográficas, 2013, 104, 685-693.	0.4	9
326	Periungual Acral Fibrokeratoma: Surgical Excision Using a Banner Flap. Actas Dermo-sifiliográficas, 2013, 104, 830-832.	0.4	6
327	Cera para huesos en la cirugía dermatológica. Actas Dermo-sifiliográficas, 2013, 104, 299-303.	0.4	9
328	Adherence and Patient Satisfaction With Topical Treatment in Psoriasis, and the Use, and Organoleptic Properties of Such Treatments: A Delphi Study With an Expert Panel and Members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermo-sifiliográficas, 2013, 104, 488-496.	0.4	19
329	Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study. Actas Dermo-sifiliográficas, 2013, 104, 807-814.	0.4	0
330	Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. British Journal of Dermatology, 2013, 168, 820-824.	1.5	52
331	Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1387-1404.	2.4	105
332	Fibroqueratoma acral periungueal: exéresis quirúrgica en bandera. Actas Dermo-sifiliográficas, 2013, 104, 830-832.	0.4	5
333	Expert Report on Psoriasis: Spanish Dermatologists'™ Opinions on the Use of Biologic Agents to Manage Moderate to Severe Psoriasis in Adults. Actas Dermo-sifiliográficas, 2013, 104, 400-408.	0.4	2
334	Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. Actas Dermo-sifiliográficas, 2013, 104, 694-709.	0.4	32
335	Actualización en dermatopatología. Actas Dermo-sifiliográficas, 2013, 104, 204-211.	0.4	1
336	Adherencia y satisfacción del paciente y características organolépticas y de uso de los tratamientos tópicos utilizados para la psoriasis: Consenso Delphi del panel de expertos y miembros del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermo-sifiliográficas, 2013, 104, 488-496.	0.4	43
337	Bone Wax in Dermatologic Surgery. Actas Dermo-sifiliográficas, 2013, 104, 299-303.	0.4	3
338	Condrodermatitis nodularis helioides tratada con éxito con nitroglicerina al 2% en gel. Actas Dermo-sifiliográficas, 2013, 104, 531-532.	0.4	10
339	Informe de expertos en psoriasis: opinión de los dermatólogos españoles sobre el manejo de la psoriasis moderada-grave con agentes biológicos en pacientes adultos. Actas Dermo-sifiliográficas, 2013, 104, 400-408.	0.4	10
340	Biosimilars in Dermatology: Starting With Infliximab. Actas Dermo-sifiliográficas, 2013, 104, 175-180.	0.4	5
341	Psoriasis y su relación con el síndrome metabólico. Revista Colombiana De Reumatología, 2013, 20, 228-236.	0.1	1
342	Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study. Actas Dermo-sifiliográficas, 2013, 104, 807-814.	0.4	19

#	ARTICLE	IF	CITATIONS
343	Biosimilares en dermatología: infliximab para empezar. Actas Dermo-sifiliográficas, 2013, 104, 175-180.	0.4	6
344	Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. British Journal of Dermatology, 2013, 168, 609-616.	1.5	85
345	Shortcomings of PASI75 and practical calculation of PASI area component. Journal of the American Academy of Dermatology, 2013, 68, 180-181.	1.2	15
346	The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). Journal of Dermatological Treatment, 2013, 24, 169-178.	2.2	59
347	Sonication versus Vortexing of Implants for Diagnosis of Prosthetic Joint Infection. Journal of Clinical Microbiology, 2013, 51, 591-594.	3.9	92
348	Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. British Journal of Dermatology, 2013, 169, 1141-1147.	1.5	46
349	Pseudocystic Encapsulation: A Late Noninflammatory Complication of Hyaluronic Acid Filler Injections. Dermatologic Surgery, 2013, 39, 1726-1728.	0.8	13
350	Anti-tumour necrosis factor- $\alpha$ treatment and weight gain in psoriasis: the "pudgy blanching" conundrum. British Journal of Dermatology, 2013, 168, 923-924.	1.5	2
351	Photoallergic contact dermatitis caused by benzophenones in magazine inks. Contact Dermatitis, 2013, 69, 124-126.	1.4	22
352	Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios. British Journal of Dermatology, 2013, 168, 674-676.	1.5	8
353	SAT0018...Identification of new epistatic interactions with the HLA region in the genetic etiology of psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases, 2013, 71, 477.1-477.	0.9	0
354	Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life. European Journal of Dermatology, 2013, 23, 407-408.	0.6	5
355	AB0017...Association study of genetic risk variants for psoriasis in a large cohort of psoriatic arthritis, psoriasis and controls of the spanish population and association with relevant clinical subphenotypes. Annals of the Rheumatic Diseases, 2013, 71, 638.4-638.	0.9	0
356	Validation of the Spanish Acne Severity Scale (Escala de Gravedad del Acn $\acute{e}$ Española "EGAE). European Journal of Dermatology, 2013, 23, 233-240.	0.6	9
357	Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. Human Molecular Genetics, 2012, 21, 4549-4557.	2.9	79
358	Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up. Dermatology, 2012, 225, 220-230.	2.1	13
359	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. European Journal of Dermatology, 2012, 22, 762-769.	0.6	25
360	Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review. Dermatology, 2012, 225, 14-17.	2.1	68

#	ARTICLE	IF	CITATIONS
361	Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 56.	2.4	19
362	Riesgo cardiovascular y psoriasis: papel de la terapia biológica. <i>Actas Dermo-sifiliográficas</i> , 2012, 103, 853-862.	0.4	20
363	Respuesta a: Sobre las ecuaciones para estimar el riesgo vascular en pacientes con psoriasis (REGICOR y Tj ETQq1 1 0.784314 rgBT / O	0.4	0
364	Cardiovascular Risk and Psoriasis: the Role of Biologic Therapy. <i>Actas Dermo-sifiliográficas</i> , 2012, 103, 853-862.	0.4	11
365	Response to: "On Cardiovascular Risk Estimation in Patients With Psoriasis: The REGICOR and SCORE Scales". <i>Actas Dermo-sifiliográficas</i> , 2012, 103, 943-944.	0.4	0
366	Multiplex PCR of sonication fluid accurately differentiates between prosthetic joint infection and aseptic failure. <i>Journal of Infection</i> , 2012, 65, 541-548.	3.3	155
367	Ustekinumab in clinical practice: response depends on dose and previous treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 508-513.	2.4	32
368	Treatment of severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 17-18.	2.4	2
369	Narrowband UV-B, Monochromatic Excimer Laser, and Photodynamic Therapy in Psoriasis: A Consensus Statement of the Spanish Psoriasis Group. <i>Actas Dermo-sifiliográficas</i> , 2011, 102, 175-186.	0.4	4
370	Clinical Characteristics and Disease Course in Patients Treated With Efalizumab Following Suspension of Marketing Authorization by the European Medicines Agency: A Multicenter Observational Study. <i>Actas Dermo-sifiliográficas</i> , 2011, 102, 354-364.	0.4	0
371	Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1007-1011.	2.4	166
372	Uso de biológicos en la psoriasis durante el embarazo. <i>Piel</i> , 2011, 26, 40-45.	0.0	0
373	Grover Disease: A Reappraisal of Histopathological Diagnostic Criteria in 120 Cases. <i>American Journal of Dermatopathology</i> , 2010, 32, 541-549.	0.6	58
374	EADV preceptorship: advances in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 2-24.	2.4	11
375	Juvenile psoriasis and its clinical management: a European expert group consensus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 812-818.	0.8	33
376	Juvenile Psoriasis und ihre Behandlungsmöglichkeiten: Konsensus einer europäischen Expertengruppe. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 812-819.	0.8	20
377	Treatment of Acrodermatitis Continua of Hallopeau with TNF-Blocking Agents: Case Report and Review. <i>Dermatology</i> , 2010, 220, 154-158.	2.1	44
378	Treatment of Psoriasis with Anti-TNF Drugs during Pregnancy: Case Report and Review of the Literature. <i>Dermatology</i> , 2010, 220, 71-76.	2.1	64

#	ARTICLE	IF	CITATIONS
379	Biosimilars or Follow-on Biologics in Dermatology. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 4-6.	0.4	0
380	Commentary on European and British Guidelines for the Treatment of Psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 285-290.	0.4	0
381	Treatment of Scalp Psoriasis: Review of the Evidence and Delphi Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 827-846.	0.4	6
382	Carcinoma epidermoide infiltrante de clitoris en paciente de 30 años, no ligado a infección por virus del papiloma humano. <i>Progresos En Obstetricia Y Ginecología</i> , 2010, 53, 72-75.	0.0	0
383	Biosimilares o biosecuelas en Dermatología. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 4-6.	0.4	0
384	Comentarios a las directrices europeas y británicas sobre el tratamiento de la psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 285-290.	0.4	8
385	Artritis psoriásica: lo que el dermatólogo debe saber (Parte 1). <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 578-584.	0.4	6
386	Artritis psoriásica. Lo que el dermatólogo debe saber (Parte 2). <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 742-748.	0.4	4
387	Metotrexato: guía de uso en psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 600-613.	0.4	65
388	Tratamiento de la psoriasis del cuero cabelludo. Revisión de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 827-846.	0.4	13
389	Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1785-1796.	0.7	554
390	Pityriasis lichenoides chronica induced by infliximab, with response to methotrexate. <i>European Journal of Dermatology</i> , 2010, 20, 511-512.	0.6	13
391	Identifying the biologic closest to the ideal to treat chronic plaque psoriasis in different clinical scenarios: using a pilot multi-attribute decision model as a decision-support aid. <i>Current Medical Research and Opinion</i> , 2009, 25, 2835-2843.	1.9	10
392	Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 469-475.	1.3	15
393	Scalp psoriasis: European consensus on grading and treatment algorithm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1435-1444.	2.4	79
394	Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiliográficas</i> , 2009, 100, 277-286.	0.4	95
395	Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. <i>Actas Dermo-sifiliográficas</i> , 2009, 100, 386-413.	0.4	73
396	Reactions to Infliximab Infusions in Dermatologic Patients: Consensus Statement and Treatment Protocol. <i>Actas Dermo-sifiliográficas</i> , 2009, 100, 103-112.	0.4	1

#	ARTICLE	IF	CITATIONS
397	Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiliogrÁficas</i> , 2009, 100, 277-288.	0.4	11
398	Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. <i>Actas Dermo-sifiliogrÁficas</i> , 2009, 100, 386-413.	0.4	14
399	Granulomatous septal panniculitis associated with capecitabine (Xeloda®). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 121-122.	2.4	10
400	Efficacy in reducing potassium load in irradiated red cell bags with a potassium adsorption filter. <i>Transfusion</i> , 2008, 48, 1966-1970.	1.6	25
401	Seroprevalence of <i>Trypanosoma cruzi</i> infection in at-risk blood donors in Catalonia (Spain). <i>Transfusion</i> , 2008, 48, 1862-1868.	1.6	119
402	Enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence testing in a bullous pemphigoid and pemphigoid gestationis. <i>International Journal of Dermatology</i> , 2008, 47, 1245-1249.	1.0	53
403	Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. <i>Transfusion and Apheresis Science</i> , 2008, 39, 115-121.	1.0	17
404	Eccrine Squamous Syringometaplasia Secondary to Pegylated Liposomal Doxorubicin. <i>Archives of Dermatology</i> , 2008, 144, 1402-3.	1.4	10
405	Cutaneous adverse effects of biological therapies for psoriasis. <i>European Journal of Dermatology</i> , 2008, 18, 693-9.	0.6	7
406	Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients. <i>Dermatology</i> , 2007, 215, 3-17.	2.1	30
407	Expression profiles associated with aggressive behavior in Merkel cell carcinoma. <i>Modern Pathology</i> , 2007, 20, 90-101.	5.5	84
408	Bortezomib-associated cutaneous vasculitis. <i>British Journal of Dermatology</i> , 2007, 157, 799-801.	1.5	40
409	Successful treatment of oral erosive lichen planus with mycophenolate mofetil. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 259-60.	2.4	34
410	Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, S119-S120.	1.2	23
411	Pigmented Paget's disease in a man previously treated with mammoplasty reduction for gynecomastia. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, S62-S63.	1.2	12
412	Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 69-74.	2.4	66
413	Blepharochalasia and double lip: diagnosis and treatment of Ascher's syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 1390-1391.	2.4	10
414	Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. <i>British Journal of Dermatology</i> , 2006, 154, 1213-1216.	1.5	49



#	ARTICLE	IF	CITATIONS
415	Factors affecting meniscal extrusion: correlation with MRI, clinical, and arthroscopic findings. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2006, 14, 394-398.	4.2	87
416	Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma. <i>Histopathology</i> , 2005, 46, 614-621.	2.9	41
417	Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. <i>British Journal of Dermatology</i> , 2005, 153, 417-423.	1.5	47
418	Onset of flexural psoriasis during infliximab treatment for Crohn's disease. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 713-714.	1.3	47
419	Consensus Statement on the Safety Profile of Topical Calcineurin Inhibitors. <i>Dermatology</i> , 2005, 211, 77-78.	2.1	54
420	Prevalencia de cicatrices en la poblaci3n espa±ola y su abordaje terap©utico. <i>Piel</i> , 2005, 20, 63-67.	0.0	1
421	Lesiones cut±neas por cupping. <i>Piel</i> , 2005, 20, 481-482.	0.0	1
422	Cutaneous necrosis after injection of polyethylene glycol±modified interferon alfa. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 62-66.	1.2	24
423	Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. <i>Journal of Dermatological Treatment</i> , 2004, 15, 146-152.	2.2	80
424	Thrombotic thrombocytopenic purpura and pregnancy: a review of ten cases. <i>Vox Sanguinis</i> , 2004, 87, 287-290.	1.5	35
425	Effect of pimecrolimus cream 1% on the long±term course of pediatric atopic dermatitis. <i>International Journal of Dermatology</i> , 2004, 43, 978-983.	1.0	33
426	Congenital Acantholytic Dyskeratotic Dermatitis: Localized Darier Disease or Disseminated Benign Papular Acantholytic Dermatitis?. <i>Pediatric Dermatology</i> , 2003, 20, 262-265.	0.9	14
427	Isotretinoin Treatment of Acne in a Patient with Apert Syndrome. <i>Pediatric Dermatology</i> , 2003, 20, 443-446.	0.9	31
428	Acantholytic dyskeratotic naevi following Blaschko's lines: a mosaic form of Darier's disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 196-199.	2.4	28
429	Topical tacrolimus 0.1% ointment (ProtopicR) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. <i>Contact Dermatitis</i> , 2003, 49, 185-188.	1.4	47
430	Leishmaniaand HIV co-infection: dermatological manifestations. <i>Annals of Tropical Medicine and Parasitology</i> , 2003, 97, 107-114.	1.6	63
431	Photocontact dermatitis due to dexketoprofen. <i>Contact Dermatitis</i> , 2002, 47, 237-237.	1.4	19
432	Multinucleate cell angiohistiocytoma: a fibrohistiocytic proliferation with increased mast cell numbers and vascular hyperplasia. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 232-237.	1.3	56

#	ARTICLE	IF	CITATIONS
433	Merkel cell (primary neuroendocrine) carcinoma of the skin with nodal metastasis showing rhabdomyosarcomatous differentiation. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 619-622.	1.3	41
434	Hepoxilin B3 and its Enzymatically Formed Derivative Trioxilin B3 are Incorporated into Phospholipids in Psoriatic Lesions. <i>Journal of Investigative Dermatology</i> , 2002, 118, 139-146.	0.7	19
435	Hypomelanosis of Ito with Sturge-Weber Syndrome-like Leptomeningeal Angiomatosis. <i>Pediatric Dermatology</i> , 2002, 19, 536-540.	0.9	16
436	Sti571-induced Stevens-Johnson Syndrome. <i>British Journal of Haematology</i> , 2002, 119, 274-275.	2.5	30
437	Multiple minute digitate hyperkeratosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2002, 16, 422-424.	2.4	12
438	Over-Expression of p45SKP2 in Kaposi's Sarcoma Correlates with Higher Tumor Stage and Extracutaneous Involvement but Is Not Directly Related to p27KIP1 Down-Regulation. <i>Modern Pathology</i> , 2002, 15, 1227-1235.	5.5	37
439	Cutaneous angiolymphoid hyperplasia with high endothelial venules is characterized by endothelial expression of cutaneous lymphocyte antigen. <i>Human Pathology</i> , 2001, 32, 227-229.	2.0	13
440	Keratosis lichenoides chronica. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 84-85.	2.4	13
441	Proliferating trichilemmal tumour: p53 immunoreactivity in association with p27Kip1 over-expression indicates a low-grade carcinoma profile. <i>Histopathology</i> , 2001, 38, 454-457.	2.9	26
442	Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. <i>Hepatology</i> , 2001, 34, 1035-1040.	7.3	74
443	Decreased immunoreactivity for cell-cycle regulator p27Kip1 in Kaposi's sarcoma correlates with higher stage and extracutaneous involvement. <i>Journal of Pathology</i> , 2000, 191, 387-393.	4.5	10
444	Dermatomyositis-like eruption following hydroxyurea therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2000, 14, 227-228.	2.4	16
445	Immunohistochemical Detection of Bcl-2 in Kaposi's Sarcoma Lesions Varies According to Histopathologic Stage, Whereas Expression of Bcl-x and Mcl-1 Differs According to Human Immunodeficiency Virus Serologic Status of Patients. <i>Modern Pathology</i> , 2000, 13, 438-445.	5.5	13
446	Differential expression of c-Met in Kaposi's sarcoma according to progression stage and HIV infection status. <i>Journal of Cutaneous Pathology</i> , 1999, 26, 227-231.	1.3	6
447	Absence of Fas (CD95) and FasL (CD95L) immunohistochemical expression suggests Fas/FasL-mediated apoptotic signal is not relevant in cutaneous Kaposi's sarcoma lesions. <i>Journal of Cutaneous Pathology</i> , 1999, 26, 417-423.	1.3	7
448	Occurrence of Hepoxilins and Trioxilins in Psoriatic Lesions. <i>Journal of Investigative Dermatology</i> , 1998, 110, 303-310.	0.7	33
449	Pityriasis lichenoides in children: clinicopathologic review of 22 patients.. <i>Pediatric Dermatology</i> , 1998, 15, 1-6.	0.9	98
450	Calcinosis Cutis Following Calcium Chloride Electrode Paste Application for Auditory Brainstem Evoked Potentials Recording. <i>Pediatric Dermatology</i> , 1998, 15, 27-30.	0.9	11

#	ARTICLE	IF	CITATIONS
451	Adams-Oliver Syndrome with Unusual Central Nervous System Alterations. <i>Pediatric Dermatology</i> , 1998, 15, 48-50.	0.9	1
452	Calcinosis cutis following calcium chloride electrode paste application for auditory-brainstem evoked potentials recording. <i>Pediatric Dermatology</i> , 1998, 15, 27-30.	0.9	25
453	Adams-Oliver syndrome with unusual central nervous system alterations. <i>Pediatric Dermatology</i> , 1998, 15, 48-50.	0.9	17
454	Brooke-Spiegler Syndrome Variant Segregation of Tumor Types with Mixed Differentiation in Two Generations. <i>American Journal of Dermatopathology</i> , 1998, 20, 56-60.	0.6	46
455	Benign Myoepithelioma of the Skin. <i>American Journal of Dermatopathology</i> , 1998, 20, 208-212.	0.6	48
456	Pharmacodynamic interaction with phototoxic plants during PUVA therapy. <i>British Journal of Dermatology</i> , 1997, 136, 973-974.	1.5	2
457	Lipodystrophia Centrifugalis Abdominalis Infantilis: A Case Report. <i>Pediatric Dermatology</i> , 1997, 14, 216-218.	0.9	11
458	ID REACTION TO MOLLUSCUM CONTAGIOSUM. <i>Pediatric Dermatology</i> , 1996, 13, 349-350.	0.9	17
459	Carbamazepine-induced drug rashes: diagnostic value of patch tests depends on clinico-pathologic presentation. <i>Contact Dermatitis</i> , 1996, 34, 435-437.	1.4	28
460	REITER'S SYNDROME-LIKE PATTERN IN AIDS-ASSOCIATED PSORIASIFORM DERMATITIS. <i>International Journal of Dermatology</i> , 1996, 35, 484-488.	1.0	36
461	Mycosis fungoides associated with unusual epidermal hyperplasia. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 61-64.	1.3	11
462	CD44 and melanocytic tumors: a possible role for standard CD44 in the epidermotropic spread of melanoma. <i>Journal of Cutaneous Pathology</i> , 1996, 23, 133-139.	1.3	18
463	Detection of antineutrophil cytoplasmic antibodies in patients with hepatitis C virus-induced cutaneous vasculitis with mixed cryoglobulinemia. <i>Archives of Dermatology</i> , 1996, 132, 974-975.	1.4	5
464	Mycosis fungoides associated with unusual epidermal hyperplasia. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 61-64.	1.3	2
465	CD44 Distribution in Sweat Gland Tumors Suggests It Has Different Functional Roles in the Various Cell Types. <i>American Journal of Dermatopathology</i> , 1996, 18, 483-489.	0.6	7
466	Mycosis fungoides associated with unusual epidermal hyperplasia. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 61-4.	1.3	2
467	Of APACHEs and PALEFACEs. <i>American Journal of Dermatopathology</i> , 1995, 17, 209.	0.6	17
468	Pigmented epidermotropic ductal carcinoma of the breast in a male. Ultrastructural evidence of melanocytic colonization and melanin transfer to the tumor. <i>Journal of Cutaneous Pathology</i> , 1995, 22, 276-280.	1.3	27

#	ARTICLE	IF	CITATIONS
469	Lipstick allergic contact dermatitis from gallates. <i>Contact Dermatitis</i> , 1995, 32, 359-360.	1.4	37
470	Erythema-multiforme-like eruption due to topical contactants: expression of adhesion molecules and their ligands and characterization of the infiltrate. <i>Contact Dermatitis</i> , 1995, 33, 329-352.	1.4	19
471	Epidermal expression of 65 and 72 kd heat shock proteins in psoriasis and AIDS-associated psoriasiform dermatitis. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 985-989.	1.2	31
472	Confluent and reticulated papillomatosis of Gougerot and Carteaud: minocycline deserves trial before etretinate. <i>Archives of Dermatology</i> , 1995, 131, 109-110.	1.4	11
473	Overexpression of p53 in disseminated superficial actinic porokeratosis with and without malignant degeneration. <i>Archives of Dermatology</i> , 1995, 131, 353-354.	1.4	12
474	Enhancement of PUVA Phototoxic Effects Following Celery Ingestion: Cool Broth Also Can Burn. <i>Archives of Dermatology</i> , 1994, 130, 809.	1.4	10
475	Interleukin-1 Increases 15-Hydroxyeicosatetraenoic Acid Production in Human Dermal Fibroblasts. <i>Journal of Investigative Dermatology</i> , 1994, 102, 98-104.	0.7	14
476	ERYTHEMA MULTIFORME-LIKE REACTION FOLLOWING DIPENCYPRONE TREATMENT OF PLANE WARTS. <i>International Journal of Dermatology</i> , 1994, 33, 201-203.	1.0	25
477	Erythema Multiformlike Reaction Caused by Topical Application of Thuja Essential Oil. <i>American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society</i> , 1994, 5, 94-97.	0.4	8
478	Enhancement of PUVA phototoxic effects following celery ingestion: cool broth also can burn. <i>Archives of Dermatology</i> , 1994, 130, 809-810.	1.4	10
479	Petechial glove and sock syndrome caused by parvovirus B19. <i>Cutis</i> , 1994, 54, 335-40.	0.3	11
480	ACUTE FEBRILE NEUTROPHILIC DERMATOSIS (SWEET'S SYNDROME). <i>International Journal of Dermatology</i> , 1993, 32, 261-268.	1.0	106
481	Epidermal Cell Polymorphonuclear Leukocyte Cooperation in the Formation of Leukotriene B4 by Transcellular Biosynthesis. <i>Journal of Investigative Dermatology</i> , 1992, 98, 333-339.	0.7	54
482	The New Labcor-Santiago Pericardial Bioprosthesis. <i>Journal of Cardiac Surgery</i> , 1991, 6, 613-619.	0.7	10
483	Cyclooxygenase Activity Is Increased in Platelets from Psoriatic Patients. <i>Journal of Investigative Dermatology</i> , 1991, 97, 922-926.	0.7	23
484	Metabolism of exogenous arachidonic acid by polymorphonuclear leukocytes from psoriatic patients. <i>Archives of Dermatological Research</i> , 1991, 283, 77-80.	1.9	11
485	Morphological Aspects Sodium lauryl sulfate stimulates the metabolism of endogenous arachidonic acid in epidermal cell suspensions. <i>Contact Dermatitis</i> , 1990, 23, 235-235.	1.4	2
486	Effect of Lonapalene on Metabolism of Exogenous Arachidonic Acid in Human Platelets. <i>Skin Pharmacology and Physiology</i> , 1989, 2, 86-92.	2.5	1

#	ARTICLE	IF	CITATIONS
487	Erythroderma due to ribostamycin. Contact Dermatitis, 1989, 21, 79-82.	1.4	6
488	Psoriasis Induced by Ophthalmic Timolol Preparations. American Journal of Ophthalmology, 1989, 108, 455-456.	3.3	19
489	Factitial dermatosis of the breast: a possible dermatologic manifestation of Munchausen's syndrome. Cutis, 1989, 44, 292-4.	0.3	8
490	Acquired Pachydermatoglyphy A Cutaneous Sign of Internal Malignancy. International Journal of Dermatology, 1988, 27, 688-689.	1.0	10
491	Erythema Gyratum Atrophicans Transiens Neonatale: A Variant of Cutaneous Neonatal Lupus Erythematosus. Pediatric Dermatology, 1988, 5, 112-116.	0.9	28
492	Cutaneous extramedullary hematopoiesis in a patient with acute myelofibrosis. Archives of Dermatology, 1988, 124, 329-331.	1.4	21
493	Allergic contact dermatitis due to ranitidine. Contact Dermatitis, 1987, 17, 54-55.	1.4	29
494	KOH Preparation for Early Diagnosis of Systemic Candidiasis in Heroin Addicts. International Journal of Dermatology, 1987, 26, 257-257.	1.0	2
495	Granulation Tissue Proliferation During Isotretinoin Treatment. International Journal of Dermatology, 1986, 25, 191-195.	1.0	9
496	Gastric adenocarcinoma in a patient with zeroderma pigmentosum. British Journal of Dermatology, 1985, 113, 632-633.	1.5	4
497	Beyond plaque psoriasis " pathogenesis and treatment of other psoriasis phenotypes. Current Opinion in Rheumatology, 0, Publish Ahead of Print, .	4.3	3